Welcome to our dedicated page for Century Therapeutics news (Ticker: IPSC), a resource for investors and traders seeking the latest updates and insights on Century Therapeutics stock.
Century Therapeutics, Inc. (NASDAQ: IPSC) is a biotechnology company at the forefront of advancing cell therapies for cancer and autoimmune diseases. Utilizing adult stem cells, specifically induced pluripotent stem cells (iPSCs), Century Therapeutics leverages its proprietary Allo-Evasion™ technology to develop curative therapies that overcome the limitations of first-generation cell therapies.
The company's innovative platform integrates several advanced technologies including CRISPR-mediated gene editing, proprietary chimeric antigen receptors (CARs), and cutting-edge manufacturing capabilities. These combined elements enhance cell product performance, prevent host immune system rejection, and minimize development risks, positioning Century Therapeutics as a leader in the biotech sector.
Key Candidates and Achievements
- CNTY-101: An investigational CD19-targeting iPSC-derived natural killer (NK) cell therapy, CNTY-101 is designed for treating relapsed or refractory non-Hodgkin lymphoma (NHL). This product incorporates six precision gene edits and has shown promising early response signals, including complete and partial responses in clinical trials.
- Allo-Evasion™ Technology: Core to Century's strategy, this technology enables repeat dosing without the need for continual lymphodepletion, significantly improving patient outcomes. The company presented comprehensive data demonstrating the protective capabilities of its Allo-Evasion™ edits at major scientific conferences.
- Dual-Targeting CARs: Century has developed a novel CD19xCD22 bispecific CAR, demonstrating effective cytotoxicity against tumors in preclinical models, further expanding the potential applications of its therapies.
Recent News and Developments
- Clinical Trial Success: The ELiPSE-1 Phase 1 trial showcased encouraging initial data for CNTY-101, revealing its potential in treating aggressive B-cell lymphomas.
- New Partnerships and Acquisitions: The acquisition of Clade Therapeutics, a leader in iPSC-derived αβ T cells, enhances Century's pipeline, technology, and expertise in the cell therapy space.
- Financial Growth: Century recently secured $60 million in private placement funding, underscoring investor confidence in its strategic direction and potential market impact.
- Research Expansion: The company is expanding its clinical development into autoimmune disease indications, with a focus on leveraging its iPSC platform to address significant unmet medical needs.
For more detailed information about Century Therapeutics and its groundbreaking work in cell therapy, visit www.centurytx.com.
Century Therapeutics (NASDAQ: IPSC) will have CEO Lalo Flores present at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 10:15 AM ET. He will also participate in a panel discussing key features in NK Cellular Therapeutics on April 14, 2022, at 11:00 AM ET. A live webcast of the presentation will be available on the company’s website, with an archived replay for 30 days post-event. Century Therapeutics focuses on developing innovative iPSC-derived cell therapies aimed at treating hematologic and solid tumor cancers.
Century Therapeutics (NASDAQ: IPSC) announced that CEO Lalo Flores, Ph.D., will present at the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, 2022. The presentation will focus on the company's development of induced pluripotent stem cell (iPSC)-derived cell therapies aimed at treating cancer. A recording will be available on their website starting March 30 at 7:00 AM ET for 90 days. Century's innovative approach seeks to advance cancer care by leveraging adult stem cells and genetic engineering.
Century Therapeutics (NASDAQ: IPSC) reported Q4 and full-year 2021 results, ending with $358.8 million in cash, ensuring operations into 2025. A strategic collaboration with Bristol Myers Squibb includes a $100 million upfront payment and a $50 million equity investment. The company plans to submit an IND for CNTY-101 in mid-2022 and initiate the Phase 1 ELiPSE-1 trial for relapsed/refractory lymphoma. R&D expenses rose to $75.6 million, contributing to a net loss of $95.8 million for 2021. The company anticipates operating expenses between $155 million and $165 million for 2022.
Century Therapeutics (NASDAQ: IPSC) announced that its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET. A live webcast of the event will be accessible on Century's website and available for replay for 90 days. The company focuses on developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, aiming to address the limitations of traditional cell therapies and enhance patient access.
Bristol Myers Squibb (NYSE:BMY) reported Q4 revenues of $12.0 billion, an 8% increase driven by robust sales of Eliquis and immuno-oncology products. Full-year revenues reached $46.4 billion, up 9%. Q4 earnings per share (EPS) stood at $1.07 (GAAP) and $1.83 (non-GAAP), with annual EPS at $3.12 and $7.51 respectively. The company announced a $15 billion share repurchase authorization and provided 2022 guidance, predicting $47 billion in revenues. The outlook includes expected growth from new products and a reduction in operating expenses.
Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have formed a collaboration to develop iPSC-derived cell therapies for hematologic malignancies. Century will receive an upfront payment of $100M and a $50M equity investment, with a total of up to $3B in potential milestone payments and royalties. The initial projects focus on acute myeloid leukemia and multiple myeloma. Bristol Myers Squibb will lead clinical development, while Century retains co-promotion rights. This partnership aims to leverage expertise in oncology and enhance the chances of successful outcomes.
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to develop allogeneic cell therapies targeting hematologic malignancies and solid tumors. Century will receive
On January 4, 2022, Century Therapeutics (NASDAQ: IPSC) announced that its CEO, Lalo Flores, Ph.D., will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. The event will cover the company's advancements in iPSC-derived cell therapies for cancer treatment. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterward. Century Therapeutics focuses on harnessing stem cells to improve patient care in oncology.
Century Therapeutics (NASDAQ: IPSC) has been selected for inclusion in the NASDAQ Biotechnology Index (NASDAQ: NBI), effective December 20, 2021. This index tracks companies in the biotechnology and pharmaceuticals segment, requiring a minimum market capitalization of $200 million and an average trading volume of at least 100,000 shares. Being part of the index can enhance visibility and attract institutional investments. Century Therapeutics focuses on developing iPSC-derived cell therapies targeting cancers, aiming to facilitate broader patient access and improve cancer treatment outcomes.
FAQ
What is the current stock price of Century Therapeutics (IPSC)?
What is the market cap of Century Therapeutics (IPSC)?
What is Century Therapeutics' primary focus?
What is CNTY-101?
How does Century Therapeutics' Allo-Evasion™ technology work?
What recent achievements has Century Therapeutics made?
What are the potential applications of Century's dual-targeting CARs?
What are Century Therapeutics' plans for autoimmune diseases?
How does Century Therapeutics ensure the safety of its cell therapies?
What financial milestones has Century Therapeutics recently achieved?
Where can I find more information about Century Therapeutics?
What partnerships does Century Therapeutics have?
